866-997-4948(US-Canada Toll Free)

Symlin (Type 2 Diabetes) Analysis and Forecasts to 2020

Published By :

GlobalData

Published Date : Oct 2011

Category :

Diabetes

No. of Pages : 34 Pages


GlobalDatas pharmaceuticals report, Symlin (Type 2 Diabetes) Analysis and Forecasts to 2020 provides Nesina sales estimates for US. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2005-2020). The report also includes information on Type 2 Diabetes market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Symlin including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Symlin including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2005-2020 for Symlin in the US market

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of Contents

1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3

2 Introduction 4
2.1 Diabetes 4
2.2 Epidemiology 4
2.2.1 Prevalence 4
2.2.2 Mortality 6
2.3 Etiology and Risk Factors 8
2.3.1 Obesity 8
2.3.2 Sedentary Lifestyle 8
2.3.3 Family History and Genetics 8
2.3.4 Ethnicity 8
2.3.5 Old Age 8
2.4 Economic Impact of Diabetes 8
2.5 GlobalData Report Guidance 10

3 Type 2 Diabetes: Market Characterization 11
3.1 Type 2 Diabetes Market 11
3.2 Type 2 Diabetes Market Forecasts 12
3.3 Type 2 Diabetes Market: Drivers and Restraints 13
3.3.1 Drivers 13
3.3.2 Restraints 14

4 Classification of Diabetes 15
4.1 Types of Diabetes 15
4.1.1 Type1 Diabetes 15
4.1.2 Type 2 Diabetes 15
4.1.3 Gestational Diabetes 15
4.2 Diabetes Complications 15
4.2.1 Cardiovascular Disease 15
4.2.2 Nephropathy 16
4.2.3 Neuropathy 16
4.2.4 Amputation 16
4.2.5 Retinopathy 16

5 Evolution of Anti-Diabetic Treatments 17

6 Medications 19

6.1 Insulin 19
6.2 Oral Medications 19
6.2.1 Sulfonylureas (SUR) 19
6.2.2 Biguanides (BGDs) 20
6.2.3 Alpha-Glucosidase Inhibitors (AGI) 21
6.2.4 Meglitinides 21
6.2.5 Thiazolidinediones (TZDs) 22
6.2.6 Dipeptidyl Peptidase IV (DPP-4) Inhibitors 23
6.2.7 Oral Combination Therapy 23
6.3 Other Injectionable Medications 23
6.3.1 Pramlintide 23
6.3.2 Exenatide 23
6.4 Market Share as per Classes in Type 2 Diabetes 24

7 Symlin 25
7.1 Introduction 25
7.2 Mechanism of Action 25
7.3 Clinical Studies 25
7.4 Approval History of Symlin 26
7.5 Factors Affecting Sales of Symlin 26
7.5.1 Unmet Medical Need In Insulin Failed Patients 26
7.5.2 Low Competition 26
7.5.3 No Increased Risk of Cardiovascular Events 26
7.5.4 Better Long Term Glucose Control 26
7.5.5 Induces Weight Loss 27
7.5.6 Risk of Severe Hypoglycemia 27
7.6 Drug Evaluation 27
7.6.1 Drug Risk Benefit Score 27
7.6.2 Intensity of Competition 29
7.7 Sales Estimates 29
7.7.1 Target Patient Pool for Symlin 29
7.7.2 Dosing 29
7.7.3 Market Penetration 29
7.7.4 Annual Cost of Therapy 30
7.7.5 Sales Projections of Symlin in the US from 2005-2020 30

8 Diabetes Market: Appendix 31
8.1 Market Definitions 31
8.2 List of Abberiviations 31
8.3 Research Methodology 31
8.3.1 Coverage 32
8.3.2 Secondary Research 32
8.3.3 Forecasting 32
8.3.4 Net Penetration of Drug 33
8.3.5 Net Annual Dosing 33
8.3.6 Annual Cost of Therapy 33
8.3.7 Primary Research 33
8.3.8 Expert Panels 34
8.4 Contact Us 34
8.5 Disclaimer 34
8.6 Sources 34

List of Table


Table 1: Diabetes, World, Prevalence Estimates for the age group 20-79 years (million), 2000-2030 4
Table 2: Diabetes, Top 10 Countries, by Prevalence (million), 2010 and 2030 6
Table 3: Diabetes, Top 10 Countries, Highest Health Expenditures ($bn), 2010 9
Table 4: Type 2 Diabetes, World, Major Marketed Drugs, 2010 11
Table 5: Type 2 Diabetes, World, Major Pipeline Products in Phase III 12
Table 6: Diabetes, Worldwide, Prevalence Estimates, 2010 and 2030 13
Table 7: Overweight*, Global, Prevalence Estimates in Males Aged 15 and above (%), 2005 14
Table 8: Diabetes Drugs Evolution 18
Table 9: Results of Placebo Controlled Trial of Symlin at 6-months in Type 2 Diabetes 26
Table 10: Drug Risk Benefit Score of Symlin 27
Table 11: Efficacy Results of Symlin in Placebo-Controlled Study on Type-2 Diabetes Patients 28
Table 12: Reported Rate of Hypoglycemia in Type 2 Diabetes Patients 28
Table 13: Adverse Events Reported with Symlin in Placebo Controlled Study 28
Table 14: Symlin, Type 2 Diabetes, The US, Sales Estimates ($m), 2005-2020 30

List of Chart


Figure 1: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (in %), 2010 5
Figure 2: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (in %), 2030 5
Figure 3: Diabetes, World, Mortality, 2010 6
Figure 4: Top 10 Causes of Mortality, Worldwide, 2008 7
Figure 5: Type 2 Diabetes, Global, Market Size Forecasts ($bn), 20102020 12
Figure 6: Mechanism of Action of Sulfonylurea 19
Figure 7: Mechanism of Action of Biguanide, Thiazolidinediones, Alpha-Glucosidase Inhibitors 20
Figure 8: Mechanism of Action of Metformin and Alpha-Glucosidase Inhibitors 21
Figure 9: Mechanism of Action of Thiazolidinediones 22
Figure 10: Mechanism of Action of DPP-IV Inhibitors 23
Figure 11: Type 2 Diabetes, Global, Market Share by Value, By Class (%), 2010 24
Figure 12: Symlin, Type 2 Diabetes, The US, Sales Estimates ($m), 2005-2020 30

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *